ArticleActa obstetricia et gynecologica Scandinavica2023
A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth.
Article in Acta obstetricia et gynecologica Scandinavica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The Panorama of Cerebral Palsy in Sweden Part XIV Shows Further Decrease in Prevalence and Severity in the Birth-Years 2015-2018.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- Antenatal magnesium sulphate for neuroprotection of preterm babies: data analysis of inequities in treatment in England 2014 to 2024.BMJ open quality · 2026Article
- Magnesium sulfate for neuroprotection before preterm birth: Uptake and adherence in clinical practice after National Guideline Implementation.Acta obstetricia et gynecologica Scandinavica · 2026Article
- International disparities in use of antenatal magnesium sulfate and antenatal steroids for the preterm baby.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Review
- Urinary 6-sulfatoxymelatonin as a predictive biomarker for brain injury in very preterm infants.Scientific reports · 2026Article
- Magnesium sulfate pharmacology for maternal and critical-care indications: mechanisms, pharmacokinetics, and the therapeutic window.Frontiers in pharmacology · 2026Review
- Case report: Near-fatal hypermagnesemia resulting from the use of Epsom salts in a patient with normal renal function.Frontiers in medicine · 2024Article
- A follow up on the feasibility after national implementation of magnesium sulfate for neuroprotection prior to preterm birth.Acta obstetricia et gynecologica Scandinavica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionThe risk for brain injury manifested as cerebral palsy is higher in very preterm born children than in term. Prenatal administration of magnesium sulfate (MgSO MATERIAL AND
methodsData on MgSO
resultsA total of 388 women were eligible and 79% received treatment with MgSO
conclusionsThere was a positive trend over time in the proportion of women receiving MgSO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.